| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| | 10-K | 10-K | 10-K/A | 10-K | 10-K/A |
| Revenues: |
| Corporate | 241.9 | 257.5 | | | |
| Pharmaceutical distribution | 172.6 | 190.7 | 145.4 | | |
| Retail pharmacy | 55.0 | 53.3 | 44.6 | | |
| Manufacturing | 14.3 | 13.6 | 10.8 | 7.7 | 7.6 |
| Other | | | | 128.4 | 101.4 |
| Total revenues | 241.9 | 257.5 | 200.8 | 136.1 | 109.0 |
| Revenue growth [+] | -6.1% | 28.2% | 47.6% | 24.9% | |
| Corporate | -6.1% | | | | |
| Pharmaceutical distribution | -9.5% | 31.1% | | | |
| Retail pharmacy | 3.2% | 19.4% | | | |
| Manufacturing | 5.3% | 25.2% | 40.2% | 1.8% | |
| Wholesale | | | | 33.4% | |
| Cost of goods sold | 193.2 | 195.7 | 152.0 | 100.6 | 79.4 |
| Gross profit | 48.7 | 61.8 | 48.8 | 35.5 | 29.6 |
| Gross margin | 20.1% | 24.0% | 24.3% | 26.1% | 27.2% |
| Selling, general and administrative [+] | 19.3 | 19.6 | 13.4 | 8.5 | 5.5 |
| Sales and marketing | 7.6 | 7.2 | 5.4 | 3.9 | 2.1 |
| General and administrative | 11.7 | 12.4 | 8.1 | 4.6 | 3.3 |
| Research and development | | | | 0.1 | 0.8 |
| EBITDA [+] | 31.2 | 43.6 | 36.6 | 28.0 | 24.0 |
| EBITDA growth | -28.5% | 19.4% | 30.7% | 16.4% | |
| EBITDA margin | 12.9% | 16.9% | 18.2% | 20.6% | 22.1% |
| Depreciation | 1.7 | 1.3 | 1.2 | 1.0 | 0.6 |
| EBITA | 29.5 | 42.3 | 35.4 | 26.9 | 23.4 |
| EBITA margin | 12.2% | 16.4% | 17.6% | 19.8% | 21.5% |
| Amortization of intangibles | 0.1 | 0.1 | | | |
| EBIT [+] | 29.4 | 42.2 | 35.4 | 26.9 | 23.4 |
| EBIT growth | -30.4% | 19.3% | 31.3% | 15.2% | |
| EBIT margin | 12.2% | 16.4% | 17.6% | 19.8% | 21.5% |
| Interest income | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.9 | 0.0 | -0.6 | -1.3 | -1.1 |
| Gain (loss) on foreign currency transactions | 0.1 | 0.1 | | | |
| Other | 0.2 | 0.2 | | | |
| Pre-tax income | 28.5 | 42.2 | 34.8 | 25.7 | 22.3 |
| Income taxes | 7.5 | 11.0 | 9.1 | 6.3 | 0.0 |
| Tax rate | 26.2% | 26.1% | 26.1% | 24.4% | 0.0% |
| Earnings from continuing ops | -5.1 | -3.9 | 25.7 | 19.4 | |
| Earnings from discontinued ops | 21.1 | 31.2 | | | |
| Net income | 16.0 | 27.3 | 25.7 | 19.4 | 0.0 |
| Net margin | 6.6% | 10.6% | 12.8% | 14.3% | 0.0% |
| |
| Basic EPS [+] | ($0.13) | ($0.10) | $0.67 | | |
| Growth | 30.1% | -115.2% | | | |
| Diluted EPS [+] | ($0.13) | ($0.10) | $0.67 | | |
| Growth | 30.1% | -115.2% | | | |
| |
| Shares outstanding (basic) [+] | 38.2 | 38.2 | 38.3 | | |
| Growth | 0.0% | -0.5% | | | |
| Shares outstanding (diluted) [+] | 38.2 | 38.2 | 38.3 | | |
| Growth | 0.0% | -0.5% | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |